Ganciclovir therapy was highly effective for treating cmv reactivation, but because ganciclovir-induced neutropenia was common, myeloid growth factors (for example, granulocyte-colony stimulating factor) were often co-administered. The gene discussed is CSF3; the disease is neutropenia.